phospholipase A2 group IIEGenealiases: GIIE sPLA2 · sPLA2-IIE
Q-omics provides the consensus-scored PLA2G2E profile across patient tissues and cancer cell-line models. PLA2G2E expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, PLA2G2E is differentially expressed in 7, with the highest sampling consensus in THCA. Additionally, PLA2G2E RNA expression shows 6,490 significant pathway-activity associations, with the highest sampling consensus in KIRC. Together, these results highlight BLCA, THCA, and KIRC as cancer lineages where PLA2G2E shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PLA2G2E — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PLA2G2E survival associations across molecular data types. PLA2G2E RNA expression shows survival associations in the most cancer types (17), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PLA2G2E RNA expression–survival associations across cancer types. High PLA2G2E expression shows unfavorable associations in COAD, ACC, KIRC and KICH, but favorable associations in BLCA and HNSC. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .006). Together, the overview and detailed table identify BLCA as the clearest survival context for PLA2G2E RNA expression.
This table summarizes PLA2G2E tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for PLA2G2E. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PLA2G2E shows lower tumor expression in HNSC and higher tumor expression in THCA, UCEC, COAD, PRAD and LIHC. The THCA box plot shows higher PLA2G2E RNA expression in tumor versus normal tissue (log2 FC = +1.084, t-test p < 0.001).
This table shows molecular features associated with PLA2G2E in patient tissues and cancer cell lines. In patient samples, PLA2G2E shows the broadest associations at the RNA and protein expression levels, with KIRC recurring as the lineage with the largest associated feature set. In cancer cell lines, PLA2G2E RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BREAST.
